ALGS logo

ALIGOS THERAPEUTICS INC

ALGSNASDAQ
πŸ† #4854 by market capEarnings Mar 3 Β· PostUS Equity
$1.22β–Ό $0.04 (βˆ’3.17%)
Market closed Β· at close
πŸ””
Track ALGS
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 3.2%
7dβ–Ό 42.0%
14dβ–Ό 70.4%
30dβ–Ό 75.1%
ytdβ–Ό 87.0%
1yβ–Ό 86.4%
🏦Market Cap
$8M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-44.6%
Declining
πŸ“ŠGross Margin
99.2%
High
πŸ’΅FCF Margin
-204.1%
Thin
βš–οΈP/S Ratio
0.2x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$1.22 – $1.30
52-Week Range
$1.18 – $13.69
Volume (shares)
3,412
Avg Volume (shares)
β€”
Shares Outstanding
6.2M
Next Earnings
2027-03-03

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
$3M
P/E Ratio
-0.2
P/S Ratio
0.2x
EPS (TTM)
$-6.34
Dividend Yield
0.00%
Dilution (1yr)
+65.3%
ALGS logo

ALIGOS THERAPEUTICS INC

ALGS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2Mβ–Ό βˆ’44.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
57.5%β–Ό βˆ’42.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$88Mβ–Ό βˆ’1.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$83Mβ–² +2.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
10.4Mβ–² +65.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$13Mβ–Ό βˆ’$16M YoY
StockOtter Β· stockotter.space

About ALIGOS THERAPEUTICS INC

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.